Cantor Fitzgerald Predicts Weaker Earnings for Rezolute

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings estimates for Rezolute, lowering the forecast to ($1.02) per share from a previous estimate of ($0.97).
• Rezolute reported a quarterly EPS of ($0.27), which fell short of the analysts' consensus estimate of ($0.22) by $0.05.
• Analysts maintain a generally positive outlook, with one firm rating the stock as a "sell" while others have issued "buy" or "outperform" ratings, and an average target price of $11.83.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Rezolute in a note issued to investors on Thursday, July 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($1.02) per share for the year, down from their prior forecast of ($0.97). The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Wedbush reissued an "outperform" rating and set a $12.00 price target on shares of Rezolute in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Rezolute currently has an average rating of "Moderate Buy" and an average price target of $11.83.

Rezolute Price Performance

NASDAQ:RZLT traded up $0.01 during trading hours on Monday, reaching $6.02. 58,651 shares of the company traded hands, compared to its average volume of 950,306. The firm's 50-day moving average is $4.72 and its 200-day moving average is $4.17. The stock has a market cap of $523.74 million, a P/E ratio of -5.23 and a beta of 1.03. Rezolute has a 1-year low of $2.21 and a 1-year high of $6.64.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05).

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Alpine Global Management LLC purchased a new stake in Rezolute during the 4th quarter worth approximately $54,000. Jeppson Wealth Management LLC purchased a new stake in Rezolute during the 1st quarter worth approximately $35,000. Retireful LLC purchased a new stake in Rezolute during the 2nd quarter worth approximately $70,000. Paloma Partners Management Co purchased a new stake in Rezolute during the 1st quarter worth approximately $48,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its holdings in Rezolute by 48.5% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock worth $97,000 after purchasing an additional 6,470 shares during the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Young-Jin Kim acquired 1,230,769 shares of the business's stock in a transaction on Friday, June 13th. The shares were bought at an average cost of $3.25 per share, with a total value of $3,999,999.25. Following the completion of the transaction, the director directly owned 8,423,386 shares of the company's stock, valued at $27,376,004.50. This trade represents a 17.11% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 1,241,345 shares of company stock worth $4,041,196 in the last ninety days. Corporate insiders own 18.39% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.